Neptune Technologies (NEPT) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Neptune Technologies (NEPT) Misses Q4 EPS by 8c
May 27, 2015 5:37 PM EDT
LAVAL, Quebec,, May 27, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq: ACST) (TSX-V: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its operating and financial results for the fourth quarter and fiscal year ended February 28, 2015.
"Acasti continues to focus on the clinical development of CaPre®," highlighted Pierre Lemieux, PhD, Acasti's Chief Operating Officer. ... More
May 27, 2015 5:37 PM EDT
LAVAL, Quebec,, May 27, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq: ACST) (TSX-V: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its operating and financial results for the fourth quarter and fiscal year ended February 28, 2015.
"Acasti continues to focus on the clinical development of CaPre®," highlighted Pierre Lemieux, PhD, Acasti's Chief Operating Officer. ... More
May 27, 2015 5:35 PM EDT
Significant progress now being achieved leading towards manufacturing excellence
Substantial revenue improvement anticipated in second quarter consistent with improved production
Australian Patent Office confirms validity of Neptune patent, triggering royalty payments
New Board nominees to bring additional strength to business
LAVAL, Québec, May 27, 2015 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq: NEPT) (TSX: NTB), announces its consolidated financial results for the fourth quarter and fiscal year ended February 28, 2015.
"Since our recent business update,... More
May 27, 2015 5:35 PM EDT
Significant progress now being achieved leading towards manufacturing excellence
Substantial revenue improvement anticipated in second quarter consistent with improved production
Australian Patent Office confirms validity of Neptune patent, triggering royalty payments
New Board nominees to bring additional strength to business
LAVAL, Québec, May 27, 2015 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq: NEPT) (TSX: NTB), announces its consolidated financial results for the fourth quarter and fiscal year ended February 28, 2015.
"Since our recent business update,... More
